Midi Health Pricing History and Trajectory: What You Need to Know

What Is Midi Health and Who Does It Serve?

Midi Health is a telehealth company focused specifically on women in perimenopause and menopause, a population that has historically been underserved by primary care. The platform connects patients with clinicians trained in hormone therapy, GLP-1 prescribing, and menopause-related metabolic conditions. Visits happen via video, and prescriptions are sent to the patient's preferred pharmacy or through mail-order partners.

The Clinical Gap Midi Is Targeting

The menopause care gap in the United States is measurable. A 2022 survey published by the Menopause Society (formerly NAMS) found that fewer than 20% of OB-GYN residency programs include formal menopause training, and a 2019 survey of 177 OB-GYNs found that only 6.8% felt adequately prepared to manage menopausal symptoms (Menopause Society guidelines, 2023). The 2023 Menopause Society position statement on hormone therapy states: "Hormone therapy remains the most effective treatment for vasomotor symptoms and has shown benefit for bone density, cardiovascular risk reduction when initiated within 10 years of menopause, and quality of life." (NAMS 2023 Hormone Therapy Position Statement)

Midi's founding premise rests on that gap. The company trained its clinician roster specifically in menopause protocols, distinguishing itself from general telehealth platforms that assign patients to any available provider.

Geographic Reach and Provider Model

As of late 2024, Midi Health operates in more than 25 states. Clinicians are primarily nurse practitioners with supplemental physician oversight, a model common across telehealth platforms and explicitly permitted under collaborative practice agreements in most U.S. States. The FDA does not regulate telehealth business models directly, but prescribing practices fall under the Ryan Haight Act for controlled substances and standard state medical board rules for non-controlled medications such as estradiol and progesterone (FDA, Telehealth and the Ryan Haight Act).

Midi Health Pricing History: Year by Year

Midi Health's pricing structure has changed notably since its 2021 launch, reflecting both investor pressure to scale and a strategic pivot toward insurance reimbursement as the primary revenue model.

2021 to 2022: Early Cash-Pay Phase

At launch in 2021, Midi Health operated largely on a direct-pay model. Initial consultation fees in this period were reported by early users at approximately $150 to $175. The company positioned itself as a premium, specialist-equivalent service and did not yet hold contracts with major commercial insurers. This is consistent with the trajectory of most telehealth startups: build the product and clinical workflows first, then pursue payer credentialing.

Payer credentialing typically takes 90 to 180 days per insurer per state, which helps explain why insurance coverage was not available at launch. The Centers for Medicare and Medicaid Services has documented the administrative burden of telehealth credentialing extensively (CMS, Telehealth Services).

2023: Insurance Expansion and Cash-Pay Stabilization

By mid-2023, Midi Health had secured contracts with several major commercial payers, including Aetna and Blue Cross Blue Shield plans in select states. Patients with in-network coverage began paying standard specialist copays, typically $30 to $75 per visit depending on plan tier. Cash-pay rates during this period rose modestly, with initial visit pricing reported at approximately $175 to $200 as the company adjusted to cover operational costs in a tighter funding environment.

The 2023 period also saw Midi Health add GLP-1 prescribing (semaglutide, tirzepatide) to its service menu, responding to high demand. GLP-1 medications are not covered by most commercial plans for weight management specifically, which created a separate cash-pay revenue stream for that service line. The FDA approved semaglutide 2.4 mg (Wegovy) for chronic weight management in June 2021 (FDA, Wegovy Approval), and tirzepatide 2.5 to 15 mg (Zepbound) in November 2023 (FDA, Zepbound Approval).

2024: Current Pricing and Trajectory

As of 2024, Midi Health's publicly visible pricing structure is:

• Initial consultation (cash pay): approximately $200
• Follow-up visit (cash pay): approximately $100
• Insurance-covered visit: standard specialist copay (varies by plan)
• GLP-1 medication cost: separate from visit fee; compounded semaglutide through partner pharmacies has ranged from $150 to $350 per month depending on dose and pharmacy

The company's investor disclosures and press releases (most recently a $60 million Series B in 2023) indicate a continued push toward insurance parity. More insurer contracts mean lower out-of-pocket costs for patients but require Midi to absorb the lower reimbursement rates that insurers impose. This dynamic commonly compresses telehealth margins, which can create downstream pressure on staffing ratios and visit length.

The pricing trajectory from 2021 to 2024 shows a roughly 14% to 33% increase in cash-pay initial visit costs ($150 at launch vs. $200 in 2024), while insurance-covered visits became available to a larger proportion of the patient base. Whether that trajectory continues upward depends on how many additional payer contracts Midi secures and whether GLP-1 demand sustains a separate revenue stream.

Is Midi Health Legit?

Midi Health is a legitimately operating telehealth platform. The relevant checks are regulatory standing, prescribing compliance, and patient safety record.

Regulatory and Licensing Status

Midi Health's prescribers hold active state licenses verifiable through individual state medical board databases. The platform does not appear on the FDA's list of illegitimate online pharmacies or unapproved drug vendors (FDA, BeSafeRx). LegitScript, which certifies online healthcare providers for compliance with applicable laws, has no public disqualification record for Midi Health as of January 2025.

The company prescribes FDA-approved hormone therapies including estradiol patches (e.g., Vivelle-Dot), estradiol gel (EstroGel), oral micronized progesterone (Prometrium), and vaginal estradiol (Vagifem/Yuvafem). These are not experimental or off-label uses. The 2023 Menopause Society position statement explicitly supports these agents as first-line treatments: "We continue to support the use of FDA-approved hormone therapy for the management of bothersome menopause symptoms." (NAMS 2023 Position Statement)

What the BBB and Patient Reviews Show

Midi Health is not accredited by the Better Business Bureau as of January 2025. The BBB profile contains a limited number of formal complaints, primarily in the categories of billing and customer service rather than clinical safety. This volume is low relative to the company's patient count, but the pattern of billing-related complaints is worth noting.

Patient reviews on third-party sites (Trustpilot, Google) show a bimodal distribution: patients who received timely HRT prescriptions and experienced symptom relief tend to rate the service highly (4 to 5 stars), while negative reviews cluster around insurance verification delays, unexpected bills after visits assumed to be covered, and difficulty reaching administrative staff.

Compounded GLP-1 Prescribing: A Specific Risk Area

Midi Health prescribes compounded semaglutide through 503B outsourcing facilities during periods of FDA-designated drug shortage. The FDA placed semaglutide on the drug shortage list, which allowed 503B compounding to proceed legally. However, the FDA issued a statement in October 2024 clarifying that the semaglutide shortage had been resolved for Wegovy, meaning 503B compounding for that specific indication must phase out (FDA, Drug Shortages). Patients receiving compounded semaglutide through Midi or any telehealth platform should verify their compound's current legal status with their prescriber.

Midi Health vs. Competing Menopause Telehealth Platforms

Several direct competitors target the same perimenopause and menopause telehealth space. Comparing pricing and model differences helps contextualize Midi's position.

Alloy Health

Alloy Health operates on a subscription model, charging approximately $49 per month for an ongoing care plan that includes clinician access and a prescription for a low-dose estradiol and progesterone combination. This is lower than Midi's cash-pay visit fees but covers a narrower clinical scope. Alloy does not accept insurance, which makes cost comparison direct: $49/month versus Midi's $200 initial visit plus $100 follow-ups.

Evernow

Evernow uses a hybrid model with a $25 monthly membership fee plus additional fees for prescriptions. Initial consultations are asynchronous, meaning no live video. This lowers cost but reduces the clinical depth of the encounter, particularly for patients with complex histories or multiple symptoms.

Gennev (now part of Unified Women's Healthcare)

Gennev's acquisition into a larger practice management group shifted its pricing structure. Visits are now billed primarily through insurance, similar to Midi's direction. Cash-pay rates were approximately $180 to $220 for initial visits before the acquisition.

The competitive field favors platforms that accept insurance, because out-of-pocket costs for uninsured or out-of-network patients remain a genuine barrier. A 2021 study in JAMA Internal Medicine found that telehealth visit costs for patients without insurance coverage averaged $79 for primary care but rose to $150 to $250 for specialist-equivalent services, with gynecology and endocrinology at the higher end (JAMA Internal Medicine, 2021, Telehealth Costs).

The Clinical Evidence Behind Midi's Core Service

Midi's core offering is hormone therapy for perimenopause and menopause. The clinical evidence supporting that offering is well-established.

Hormone Therapy Efficacy

The Women's Health Initiative (WHI), originally published in JAMA in 2002 (N=16,608), generated significant concern about breast cancer and cardiovascular risk with combined estrogen-progestin therapy. Subsequent re-analysis has substantially refined those findings. The 2017 WHI re-analysis by Manson et al., published in JAMA (N=27,347 combined trial participants), showed that women who initiated hormone therapy within 10 years of menopause had a 30% lower all-cause mortality compared with placebo (Manson et al., JAMA, 2017). This is the "timing hypothesis," and it forms the clinical basis for treating women in early perimenopause or within 10 years of final menstrual period.

Vasomotor symptoms (hot flashes, night sweats) affect approximately 75% of menopausal women, according to data from the Study of Women's Health Across the Nation (SWAN) (SWAN, NIH). Hormone therapy reduces moderate-to-severe hot flash frequency by 75% on average compared with a 25 to 30% reduction seen with placebo in randomized controlled trials (Cochrane Review, Hormone Therapy for Vasomotor Symptoms).

GLP-1 for Menopausal Weight Gain

Menopausal transition is associated with redistribution of body fat toward visceral adiposity and an average weight gain of 1.5 to 2 kg per year during perimenopause, independent of aging alone, according to a longitudinal analysis from the SWAN cohort (SWAN cohort analysis, NIH). This creates clinical rationale for GLP-1 prescribing in this population.

In the STEP-1 trial (N=1,961), semaglutide 2.4 mg subcutaneously once weekly produced a mean body weight reduction of 14.9% at 68 weeks compared with 2.4% in the placebo group (P<0.001) (Wilding et al., NEJM, 2021). The SURMOUNT-1 trial (N=2,539) showed tirzepatide 15 mg produced a mean weight reduction of 20.9% at 72 weeks versus 3.1% with placebo (Jastreboff et al., NEJM, 2022). Neither trial specifically enrolled a perimenopausal-only cohort, so direct extrapolation requires caution. However, the ADA's 2024 Standards of Care support GLP-1 receptor agonist use for weight management in adults with BMI <27 who have at least one weight-related comorbidity (ADA Standards of Care, 2024).

Midi Health Complaints: What Patients Report

Patient complaints about Midi Health fall into three consistent categories, based on publicly available reviews and BBB records.

Billing and Insurance Verification

The most common complaint involves patients being told their insurance covers a visit, completing the consultation, and then receiving a bill for the full cash-pay amount. Insurance verification in telehealth is notoriously inconsistent because eligibility checks do not guarantee coverage determination. The CMS has published guidance on this distinction, noting that real-time eligibility (RTE) checks confirm enrollment but not benefits (CMS, Telehealth Billing). Patients should request a written benefits verification before any telehealth visit, not just a verbal confirmation.

Prescription Turnaround Time

A secondary complaint involves delays between the visit and when the prescription reaches the pharmacy, sometimes running 3 to 7 days. For patients whose symptoms are severe, this delay is clinically meaningful. Platforms with asynchronous workflows or high patient volumes commonly show this pattern.

GLP-1 Compound Availability

A third complaint category emerged in late 2024 when the FDA's resolution of the semaglutide shortage disrupted compounded semaglutide supply chains. Patients who had been receiving compounded semaglutide through Midi and similar platforms reported abrupt supply interruptions with limited transition guidance from clinical staff. This is a systemic issue across the compounding telehealth sector, not unique to Midi, but the company's communication around that transition drew specific criticism.

How to Evaluate Whether Midi Health Is Right for You

Choosing a telehealth platform for menopause care involves more than cost. Clinical scope, insurance compatibility, and prescriber credentials all matter.

Step 1: Verify Insurance Before Booking

Call your insurer directly and ask whether Midi Health's NPIs (National Provider Identifiers) are in-network for your specific plan. Ask for a reference number for the call. Do not rely solely on Midi's website insurance checker, which, like most telehealth insurance tools, shows plan-level eligibility rather than benefit-level coverage.

Step 2: Check Prescriber Credentials

Midi Health's prescribers are primarily nurse practitioners. NPs are fully licensed to prescribe hormone therapy in all 50 states, but their scope of practice for complex cases varies by state. If your case involves a prior breast cancer diagnosis, a clotting disorder, or cardiovascular disease, ask specifically whether the clinician you are assigned to has experience managing HRT in those contexts. The Menopause Society's NAMS Certified Menopause Practitioner (NCMP) credential is the gold standard for clinician training in this space (NAMS, NCMP Certification).

Step 3: Understand the GLP-1 Prescribing Status

If you are seeking GLP-1 therapy through Midi, ask explicitly whether the medication being prescribed is FDA-approved branded product or compounded. As of early 2025, compounded tirzepatide remains permissible under active shortage status (FDA, Drug Shortages, Tirzepatide), while compounded semaglutide for Wegovy indication has entered a phase-out period. Branded semaglutide (Wegovy or Ozempic) will require prior authorization from your insurer, and approval rates vary considerably by plan.